5-Amino-1MQ: the NNMT inhibitor, honestly assessed

TL;DR

• It is not a peptide - 5-Amino-1MQ is a small molecule, a selective inhibitor of the enzyme NNMT.
• The mechanism is genuinely elegant - NNMT methylates nicotinamide using SAM, diverting it from the NAD+ salvage pathway, so inhibition preserves both inside fat cells.
• The animal result matches the hypothesis - in diet-induced obese mice, adipose NNMT inhibition raised NAD+ and SAM, suppressed lipogenesis and reduced body weight and white-fat mass.
• There is no human data of any kind - no published trial, no registered completed trial, and bioavailability, half-life, distribution and clearance are all uncharacterized in people.
• The NNMT inhibitor actually in human testing is a different molecule - AstraZeneca's AZD4248, at Phase 1.
• Two cautions follow from the mechanism itself - SAM is the body's principal methyl donor, so the effect is not confined to fat, and NNMT is upregulated in several cancer types.

Educational content, not medical advice. No doses or protocols appear; any use is physician-directed. 5-Amino-1MQ is not FDA-approved and is sold as an unregulated research chemical with no published human safety data.

---

Every year the optimization market produces a compound that arrives fully formed with a mechanism diagram, a confident dosing chart and no human evidence. 5-Amino-1MQ is the current example in the metabolic category. It has spread quickly because its mechanism sits at a genuinely interesting intersection - fat metabolism and NAD+ availability, the two things the longevity and body-composition audiences already care about.

The mechanism deserves the interest. The claims built on top of it do not yet have anything to stand on.

What it actually is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide. It is routinely listed on "peptide" vendor sites, which is a category error worth correcting because it affects how people reason about it - small molecules and peptides differ in absorption, distribution, metabolism and the kinds of off-target effects they produce. If a vendor calls it a peptide, that tells you something about the vendor.

It is a selective inhibitor of NNMT - nicotinamide N-methyltransferase - an enzyme highly expressed in adipose tissue and liver.

The mechanism - why it's interesting

NNMT does something metabolically expensive. It takes nicotinamide (a precursor that would otherwise be recycled into NAD+ through the salvage pathway) and methylates it into 1-methylnicotinamide, consuming a molecule of S-adenosylmethionine (SAM) in the process. Nicotinamide is removed from the NAD+ pool; SAM, the body's principal methyl donor, is spent.

In obesity, NNMT expression in fat tissue is elevated. The hypothesis follows directly: inhibit NNMT, and you preserve both the nicotinamide destined for NAD+ and the SAM pool, raising intracellular NAD+ and SAM specifically within adipocytes.

This is a more targeted proposition than oral NAD+ precursors, which raise availability systemically - a distinction that matters given the 2026 shift toward tissue-specific, precision NAD+ dosing. The animal results are consistent with the hypothesis: in diet-induced obese mice, inhibiting adipose NNMT raised intracellular NAD+ and SAM, suppressed fat-cell lipogenesis, and reduced body weight and white-fat mass.

That is a clean, coherent preclinical story. It is also the entirety of the evidence.

What the evidence shows - and where it stops

There are no human trials. A targeted PubMed search for a human clinical trial of 5-Amino-1MQ returns nothing. As of 2026 no peer-reviewed human study has been published and no completed trial appears on ClinicalTrials.gov. No published human study reports weight or fat loss as an outcome. There is no human efficacy data and no human safety data - not limited data, none.

The human pharmacology is unknown. Bioavailability, half-life, tissue distribution and elimination pathway have not been characterized in people. This is not a technicality. Dosing charts circulating online are extrapolations from mouse studies via body-surface-area conversion - a method that assumes the compound behaves comparably in human tissue, which nobody has checked.

The only NNMT inhibitor in registered human testing is a different molecule. AstraZeneca's AZD4248 is in Phase 1 safety testing. That a pharmaceutical company is investing in the target is a reasonable signal that NNMT inhibition is scientifically credible. It is not evidence for 5-Amino-1MQ specifically, and the fact that a Phase 1 is still where the regulated pathway sits is itself informative about how early this field is.

Where it would sit alongside NAD+ precursors and GLP-1s

Two comparisons are worth making, because both are used as selling points.

Versus NAD+ precursors. The proposed advantage is targeting: raising NAD+ inside adipocytes by blocking its local depletion, rather than flooding the system. Conceptually appealing, and it aligns with where the field is moving. But NMN and NR at least have human tolerability data and decades of related human evidence behind nicotinamide chemistry. Trading a compound with modest human evidence for one with none is not an upgrade in rigour, whatever the mechanistic elegance.

Versus GLP-1 receptor agonists. This comparison is where the marketing gets least defensible. Approved GLP-1 medications have large randomized human trials, published magnitude of effect, characterized adverse-event profiles and regulatory oversight - see how GLP-1 agonists work. 5-Amino-1MQ has mouse data. Positioning it as a natural or gentler alternative to GLP-1s inverts the evidence relationship entirely. Anyone whose actual goal is fat loss with muscle preservation is better served by the approaches in lose fat without losing muscle and body composition and aesthetics.

Realistic expectations and the safety unknowns

Two specific uncertainties are worth naming, because they follow from the mechanism rather than from general caution.

Methylation is systemic. NNMT inhibition preserves SAM by preventing its consumption. SAM is central to DNA methylation, neurotransmitter synthesis and phase-II detoxification. Altering the methyl-donor economy is not a contained adipose-tissue event, and what a sustained shift does in humans is unstudied.

NNMT expression is not confined to fat. The enzyme is expressed in liver and, notably, is upregulated in several cancer types, where it has been studied as a tumour marker and target. That cuts in a genuinely ambiguous direction - inhibition is being explored as an oncology strategy, which is not an alarm signal in itself. But it means the compound touches pathways with cancer relevance, in humans, with zero human data. That combination warrants caution rather than reassurance.

Add the unavoidable baseline problem: as an unregulated research chemical, identity and purity are unverified. You are estimating a dose of a substance you cannot confirm is what the label says, based on mouse conversions, with no human PK. How to choose a trustworthy peptide source covers what verification would actually require - and why most of this market cannot meet it.

The bottom line

5-Amino-1MQ has one of the more genuinely interesting mechanisms in the current metabolic market, and one of the emptiest human evidence files. It is a Tier 5 compound: preclinical only. The right description is "a validated target with an unvalidated molecule," and the right expectation for anyone using it today is that they are the trial.

If the mechanism holds up, it will most likely be a regulated NNMT inhibitor that demonstrates it - the AstraZeneca Phase 1 is the honest place to watch. Vivre's position on compounds at this tier is consistent: Vivre protocols are built on evidence that exists, and early-evidence compounds are labelled as such rather than sold as breakthroughs.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore NAD+.

Frequently asked questions

Does 5-Amino-1MQ cause fat loss? In diet-induced obese mice, NNMT inhibition reduced body weight and white-fat mass. In humans, there is no published trial data - no efficacy study of any kind. The mechanism is plausible; the human effect is entirely unestablished.

Is 5-Amino-1MQ a peptide? No. It is a small molecule (5-amino-1-methylquinolinium). It is frequently marketed on peptide vendor sites, which is a category error - and a useful signal about how carefully a given vendor is describing what it sells.

Is 5-Amino-1MQ safe? Unknown. There is no human safety data, no human pharmacokinetics, and no long-term animal safety programme of the kind a regulated compound would require. It is sold as an unregulated research chemical with unverified identity and purity.

5-Amino-1MQ or NMN? They work through different routes - 5-Amino-1MQ by blocking local NAD+ depletion in fat tissue, NMN by supplying precursor systemically. NMN has human tolerability data; 5-Amino-1MQ has none. Neither has demonstrated human fat-loss outcomes, and the 2026 evidence argues for measured, screened use of NAD+ strategies generally.

Related reading

• NAD+ vs NMN vs NR · Is NAD+ overrated? The precision-dosing shift · Mitochondria and ageing · Body composition and aesthetics · Lose fat without losing muscle
• Part of The Complete Guide to Mitochondrial Health

---

Educational content, not medical advice. 5-Amino-1MQ is not FDA-approved, has no published human clinical trial data of any kind, and is sold as an unregulated research chemical with unverified identity and purity. Human bioavailability, half-life and safety are uncharacterized; circulating dosing guidance is extrapolated from rodent studies. NNMT is expressed in multiple tissues and upregulated in several cancers. No doses or protocols appear here. Claims for the Malaysian market are subject to MAB requirements.

References

• 5-Amino-1MQ (5-amino-1-methylquinolinium): small-molecule selective NNMT inhibitor, not a peptide. · Mechanism: NNMT methylates nicotinamide to 1-methylnicotinamide using SAM as methyl donor, diverting nicotinamide from the NAD+ salvage pathway; NNMT expression elevated in obese adipose tissue and liver. · Preclinical: in diet-induced obese mice, adipose NNMT inhibition raised intracellular NAD+ and SAM, suppressed lipogenesis, and reduced body weight and white-fat mass. · Human evidence: no peer-reviewed human clinical trial published and no completed trial registered on ClinicalTrials.gov as of 2026; no human study reporting weight or fat loss as an outcome; human bioavailability, half-life, tissue distribution and elimination pathway uncharacterized. · Regulated comparator: AstraZeneca AZD4248, a structurally distinct NNMT inhibitor, in Phase 1 safety testing. · NNMT is upregulated in several cancer types and studied as an oncology target.